1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The promises and potential pitfalls of pharmacokinetic model–based dosing in cellular therapy
    Correspondence

    Scordo, M.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • A novel JAK2 fusion in T-cell prolymphocytic leukemia
    Meeting Abstract

    Eren, O. C.; Stuver, R.; Zhou, T.; Zaidinski, M.; Moskowitz, A. J.; Horwitz, S. M.; Ewalt, M. D.; Zhang, Y.; Lim, M.
    Virchows Archiv (2024)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P.; Ramsingh, G.; Prabhakar, P.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • CAR T-cell-derived TNF drives cytokine release syndrome and enhances M1 macrophage differentiation
    Meeting Abstract

    Lindenbergh, P. L.; Giavridis, T.; Vivier, O.; Lopez, M.; Dobrin, A.; Sadelain, M.
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Loss of heterozygosity is low for specific HLA alleles in cancer patients with driver mutations
    Meeting Abstract

    Roy, C.; Sewastianik, T.; Halvey, P.; Montesion, M.; Jindal, A.; Vallaster, M.; Lam, H.; Garrity, S.; Shapiro, G.; Klebanoff, C. A.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • THRIVE(TM) non-viral targeted transgene knock-in platform generates specific and potent TCR T cell products for the treatment of solid cancers
    Meeting Abstract

    Narayan, S.; Swanson, N.; Drain, A.; Gareau, K.; Rouillard, N.; Liang, J.; Liu, H. W.; Brown, L.; Lamothe, R.; Greenberg, P. D.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1B, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A.; Raza, M.; Acosta, J.; Mueller, P. Y.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment
    Meeting Abstract

    Terpos, E.; Ntanasis-Stathopoulos, I.; Kyriakou, C.; Tan, C.; Abildgaard, N.; Delforge, M.; Fantl, D.; Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save